Systemic Immunity Is Required for Effective Cancer Immunotherapy

Cell. 2017 Jan 26;168(3):487-502.e15. doi: 10.1016/j.cell.2016.12.022. Epub 2017 Jan 19.

Abstract

Immune responses involve coordination across cell types and tissues. However, studies in cancer immunotherapy have focused heavily on local immune responses in the tumor microenvironment. To investigate immune activity more broadly, we performed an organism-wide study in genetically engineered cancer models using mass cytometry. We analyzed immune responses in several tissues after immunotherapy by developing intuitive models for visualizing single-cell data with statistical inference. Immune activation was evident in the tumor and systemically shortly after effective therapy was administered. However, during tumor rejection, only peripheral immune cells sustained their proliferation. This systemic response was coordinated across tissues and required for tumor eradication in several immunotherapy models. An emergent population of peripheral CD4 T cells conferred protection against new tumors and was significantly expanded in patients responding to immunotherapy. These studies demonstrate the critical impact of systemic immune responses that drive tumor rejection.

Keywords: cancer immunotherapy; immune responses; immunotherapy; mass cytometry; secondary lymphoid organs; single-cell analysis; systems immunology; tumor immunology; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • B7-H1 Antigen / antagonists & inhibitors
  • Bone Marrow / immunology
  • Cell Proliferation
  • Disease Models, Animal
  • Female
  • Humans
  • Immune Tolerance
  • Immunotherapy*
  • Killer Cells, Natural / immunology
  • Lymphocyte Activation
  • Lymphoid Tissue / immunology
  • Male
  • Melanoma / immunology
  • Melanoma / therapy
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • T-Lymphocyte Subsets / immunology*
  • Triple Negative Breast Neoplasms / immunology
  • Triple Negative Breast Neoplasms / therapy
  • Tumor Microenvironment

Substances

  • B7-H1 Antigen